http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
-
Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research
-
Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
-
Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015
-
Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015
-
Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
-
FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
-
Amgen To Present At The Credit Suisse 24th Annual Healthcare Conference
-
Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015
-
Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting
-
Amgen To Highlight Cardiovascular Portfolio At American Heart Association Scientific Sessions 2015
-
Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72
-
FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US
-
Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
-
Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
-
Amgen Announces Webcast of 2015 Third Quarter Financial Results
-
Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene Laherparepvec)
-
Amgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students
-
Amgen Announces 2015 Fourth Quarter Dividend
-
Amgen And LabCentral Announce 2015 Golden Ticket Winners
-
Pre-Open Stock Movers 10/13: (WPP) (PLX) (TWTR) Higher; (EOX) (HTWR) (FMC) Lower (more...)
-
New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis
-
New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide
-
New Data Show Greater Bone Mineral Density Gains With Prolia® (Denosumab) Compared With Zoledronic Acid
-
Amgen Announces Repatha™ Co-Preferred Position on Express Scripts National Formulary
-
Amgen To Give 23 Presentations On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting
-
Amgen To Present At The Barclays Biosimilars Symposium
-
Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
-
Amgen To Present New Kyprolis® (carfilzomib) Data At 15th International Myeloma Workshop
-
Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215
-
Biotechs Pressured Following Clinton Tweet (IBB)
-
FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma
-
Amgen To Acquire Privately-Held Dezima Pharma
-
Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation
-
Amgen To Present At The Bank Of America Merrill Lynch Global Healthcare Conference
-
Amgen Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015
-
Amgen To Present At The Morgan Stanley Global Healthcare Conference
-
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)
-
Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency
-
Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs
-
Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide
-
FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)
-
Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015
-
Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)
-
Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs
-
Amgen Announces Appointment Of Fred Hassan To Board Of Directors
-
Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57
-
Amgen Announces 2015 Third Quarter Dividend
-
Amgen Announces Webcast of 2015 Second Quarter Financial Results
-
FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

